UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 46

Sortiert nach

Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Digestive diseases and sciences, 2022-03, Vol.67 (3), p.1018-1035

2022

Link zum Volltext

Verfügbarkeit prüfen

Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience

Journal of Crohn's and colitis, 2020-10, Vol.14 (10), p.1385-1393

2020

Link zum Volltext

Verfügbarkeit prüfen

Biomarkers in inflammatory bowel disease: a practical guide

Therapeutic advances in gastroenterology, 2024-01, Vol.17, p.17562848241251600-17562848241251600

2024

Link zum Volltext

Verfügbarkeit prüfen

Can We Predict the Toxicity and Response to Thiopurines in Inflammatory Bowel Diseases?

Frontiers in medicine, 2019-11, Vol.6, p.279-279

2019

Link zum Volltext

Verfügbarkeit prüfen

Amoebic colitis masquerading as inflammatory bowel disease for a decade

New Zealand medical journal, 2023-04, Vol.136 (1573), p.117-119

2023

Link zum Volltext

Verfügbarkeit prüfen

Ulcerative colitis

The Lancet (British edition), 2023-08, Vol.402 (10401), p.571-584

2023

Link zum Volltext

Verfügbarkeit prüfen

Depression, anxiety, and stress among inflammatory bowel disease patients during COVID‐19: A UK cohort study

JGH open, 2022-01, Vol.6 (1), p.76-84

2022

Link zum Volltext

Verfügbarkeit prüfen

Target Trial Emulation: Improving the Quality of Observational Studies in Inflammatory Bowel Disease Using the Principles of Randomized Trials

Inflammatory bowel diseases, 2024-06

2024

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response

Frontline gastroenterology, 2020-05, Vol.11 (3), p.188-193

2020

Link zum Volltext

Verfügbarkeit prüfen

Amoebic colitis masquerading as inflammatory bowel disease for a decade

New Zealand medical journal, 2023-04, Vol.136 (1573), p.124-127

2023

Link zum Volltext

Verfügbarkeit prüfen

Navigating the complexities of drug development for inflammatory bowel disease

Nature reviews. Drug discovery, 2024-05, Vol.23 (7), p.546-562

2024

Link zum Volltext

Verfügbarkeit prüfen

Are All Janus Kinase Inhibitors for Inflammatory Bowel Disease the Same?

Gastroenterology & hepatology, 2023-12, Vol.19 (12), p.727-738

2023

Link zum Volltext

Verfügbarkeit prüfen

5-ASAs in Crohn’s Disease: Time to Stop the Salicylate?

Digestive diseases and sciences, 2022-07, Vol.67 (7), p.2699-2700

2022

Link zum Volltext

Verfügbarkeit prüfen

Editorial: is tofacitinib another rescue option for acute severe ulcerative colitis?

Alimentary pharmacology & therapeutics, 2021-08, Vol.54 (3), p.341-342

2021

Link zum Volltext

Verfügbarkeit prüfen

An update on the safety of long-term vedolizumab use in inflammatory bowel disease

Expert opinion on drug safety, 2023-09, Vol.22 (9), p.767-776

2023

Link zum Volltext

Verfügbarkeit prüfen

Review article: Externally derived control arms—An opportunity for clinical trials in inflammatory bowel disease?

Alimentary pharmacology & therapeutics, 2023-10, Vol.58 (7), p.659-667

2023

Link zum Volltext

Verfügbarkeit prüfen

Basket, Umbrella, and Platform Trials: The Potential for Master Protocol–Based Trials in Inflammatory Bowel Disease

Gastroenterology (New York, N.Y. 1943), 2024-04

2024

Link zum Volltext

Verfügbarkeit prüfen

JAK inhibitors for the treatment of inflammatory bowel disease: results of an international survey of perceptions, attitudes, and clinical practice

European journal of gastroenterology & hepatology, 2023-11, Vol.35 (11), p.1270

2023

Link zum Volltext

Verfügbarkeit prüfen

Editorial: protecting hypoxia‐inducible factor‐1α and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis?

Alimentary pharmacology & therapeutics, 2022-03, Vol.55 (6), p.733-734

2022

Link zum Volltext

Verfügbarkeit prüfen

Su1933 – Anti-Mycobacterium Paratuberculous Therapy in Crohn’s Disease: Outcomes from Tertiary IBD Referral Centres

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-666-S-666

2019

Link zum Volltext

Verfügbarkeit prüfen

Patient and Public Involvement in Research: Lessons for Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2023-11, Vol.17 (11), p.1882-1891

2023

Link zum Volltext

Verfügbarkeit prüfen

Tu1502: SAFETY ANALYSIS OF TOFACITINIB IN ULCERATIVE COLITIS: REAL-WORLD OUTCOMES FROM A THREE-YEAR UK OBSERVATIONAL COHORT STUDY

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-989

2022

Link zum Volltext

Verfügbarkeit prüfen

Tu1501: LONGER-TERM TOFACITINIB EFFECTIVENESS FOR THE TREATMENT OF ULCERATIVE COLITIS: TWO-YEAR OUTCOMES FROM A UK OBSERVATIONAL COHORT STUDY

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-988-S-989

2022

Link zum Volltext

Verfügbarkeit prüfen

Ustekinumab-Induced Inflammatory Demyelinating Polyneuropathy in a Patient with Ulcerative Colitis

Journal of Crohn's and colitis, 2023-01, Vol.17 (1), p.144-145

2023

Link zum Volltext

Verfügbarkeit prüfen

Tofacitinib in Acute Severe Ulcerative Colitis—A Real-World Tertiary Center Experience

Inflammatory bowel diseases, 2020-11, Vol.26 (11), p.e147-e149

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(45)
Berichte
(1)

Sprache

Englisch
(46)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(29)
Science & Technology
(29)
Gastroenterology & Hepatology
(23)
Inflammatory Bowel Disease
(18)
Ulcerative Colitis
(15)
Humans
(12)
Endoscopy
(7)
Crohn's Disease
(6)
Crohns Disease
(6)
Patients
(6)
Pharmacology & Pharmacy
(6)
Remission
(6)
Clinical Trials
(5)
Colitis, Ulcerative - Drug Therapy
(5)
Crohn’s Disease
(5)
Inflammatory Bowel Diseases - Drug Therapy
(4)
Monoclonal Antibodies
(4)
Clinical Medicine
(3)
Colitis
(3)
Colonoscopy
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience

Biomarkers in inflammatory bowel disease: a practical guide

Can We Predict the Toxicity and Response to Thiopurines in Inflammatory Bowel Diseases?

Amoebic colitis masquerading as inflammatory bowel disease for a decade

Ulcerative colitis

Depression, anxiety, and stress among inflammatory bowel disease patients during COVID‐19: A UK cohort study

Target Trial Emulation: Improving the Quality of Observational Studies in Inflammatory Bowel Disease Using the Principles of Randomized Trials

Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response

Amoebic colitis masquerading as inflammatory bowel disease for a decade

Navigating the complexities of drug development for inflammatory bowel disease

Are All Janus Kinase Inhibitors for Inflammatory Bowel Disease the Same?

5-ASAs in Crohn’s Disease: Time to Stop the Salicylate?

Editorial: is tofacitinib another rescue option for acute severe ulcerative colitis?

An update on the safety of long-term vedolizumab use in inflammatory bowel disease

Review article: Externally derived control arms—An opportunity for clinical trials in inflammatory bowel disease?

Basket, Umbrella, and Platform Trials: The Potential for Master Protocol–Based Trials in Inflammatory Bowel Disease

JAK inhibitors for the treatment of inflammatory bowel disease: results of an international survey of perceptions, attitudes, and clinical practice

Editorial: protecting hypoxia‐inducible factor‐1α and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis?

Su1933 – Anti-Mycobacterium Paratuberculous Therapy in Crohn’s Disease: Outcomes from Tertiary IBD Referral Centres

Patient and Public Involvement in Research: Lessons for Inflammatory Bowel Disease

Tu1502: SAFETY ANALYSIS OF TOFACITINIB IN ULCERATIVE COLITIS: REAL-WORLD OUTCOMES FROM A THREE-YEAR UK OBSERVATIONAL COHORT STUDY

Tu1501: LONGER-TERM TOFACITINIB EFFECTIVENESS FOR THE TREATMENT OF ULCERATIVE COLITIS: TWO-YEAR OUTCOMES FROM A UK OBSERVATIONAL COHORT STUDY

Ustekinumab-Induced Inflammatory Demyelinating Polyneuropathy in a Patient with Ulcerative Colitis

Tofacitinib in Acute Severe Ulcerative Colitis—A Real-World Tertiary Center Experience

Suchergebnisse filtern